Top Page
Theratechnologies
(TSX:TH)
Theratechnologies (TH) vs. S&P 500 (SPY)
Theratechnologies Business Overview & Revenue Model
Theratechnologies Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 88.67M | 85.87M | 81.76M | 80.06M | 69.82M | 66.05M | Gross Profit |
| 70.02M | 65.42M | 62.13M | 53.78M | 46.56M | 39.15M | EBIT |
| 12.31M | 8.17M | -10.63M | -39.91M | -25.24M | -17.96M | EBITDA |
| 9.15M | 6.88M | -8.91M | -27.83M | -17.25M | -9.18M | Net Income Common Stockholders |
| -3.71M | -8.31M | -23.96M | -47.24M | -31.73M | -22.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.34M | 9.62M | 40.85M | 33.07M | 40.35M | 20.77M | Total Assets |
| 56.45M | 53.34M | 77.77M | 93.26M | 119.21M | 100.14M | Total Debt |
| 50.35M | 45.61M | 58.97M | 66.71M | 56.74M | 55.38M | Net Debt |
| 46.45M | 39.71M | 24.87M | 42.85M | 36.35M | 42.65M | Total Liabilities |
| 80.92M | 78.61M | 98.64M | 115.83M | 101.45M | 96.92M | Stockholders Equity |
| -24.47M | -25.27M | -20.87M | -22.57M | 17.76M | 3.22M |
| Cash Flow | Free Cash Flow | ||||
| -17.26M | 879.00K | -7.50M | -15.68M | -14.64M | -13.59M | Operating Cash Flow |
| -5.66M | 2.38M | -5.68M | -14.69M | -14.48M | -13.55M | Investing Cash Flow |
| -6.09M | 942.00K | 1.11M | 8.68M | -12.45M | 4.78M | Financing Cash Flow |
| -16.55M | -21.49M | 14.78M | 9.66M | 34.56M | -7.23M |
Theratechnologies Technical Analysis
Theratechnologies Risk Analysis
Theratechnologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | C$123.89M | 17.21 | 20.84% | 1.72% | 10.89% | 16.21% | |
73 Outperform | $319.41M | 24.25 | 9.69% | ― | 84.83% | -58.69% | |
60 Neutral | C$148.79M | ― | -23.05% | ― | -3.73% | 32.70% | |
54 Neutral | $161.39M | ― | ― | 16.23% | 85.76% | ||
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% | |
52 Neutral | C$9.08M | ― | -5.11% | ― | 0.98% | -13.31% | |
51 Neutral | C$9.88M | ― | -18.52% | ― | 1.14% | -36.66% |
Theratechnologies Earnings Call Summary
Theratechnologies Corporate Events
Theratechnologies has announced that it is in exclusive discussions with a potential acquiror for the sale of the company, following unsolicited acquisition proposals from Future Pak. The company has rejected Future Pak’s offers due to inadequate terms and is negotiating a definitive agreement with the potential acquiror, which includes a ‘go shop’ provision allowing engagement with other potential buyers. A special committee of independent directors is overseeing the process, assisted by financial and legal advisors, to ensure the best interests of the company and its stakeholders.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies faces significant challenges with profitability and high financial leverage, which weigh heavily on the stock’s attractiveness. While there are noteworthy improvements in revenue growth and strategic FDA approvals, these are overshadowed by technical and valuation weaknesses. Investors should be cautious and monitor ongoing operational adjustments and financial stability improvements.
To see Spark’s full report on TSE:TH stock, click here.
Theratechnologies reported a strong first quarter for 2025, with a 17% increase in total revenue year-over-year, reaching $19 million. The company received FDA approval for EGRIFTA WR™, a new formulation to treat excess visceral abdominal fat in adults with HIV and lipodystrophy, which is expected to drive future growth. Despite a temporary supply disruption for EGRIFTA SV®, the company resumed distribution and anticipates a one-time revenue impact of $10 to $12 million for the fiscal year. The approval of a Prior Approval Supplement by the FDA allows for regular distribution of EGRIFTA SV®, strengthening the company’s market position.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies faces significant challenges with profitability and high financial leverage, which weigh heavily on the stock’s attractiveness. While there are noteworthy improvements in EBITDA and strategic partnerships, these are overshadowed by technical and valuation weaknesses. Investors should be cautious and monitor ongoing operational adjustments and financial stability improvements.
To see Spark’s full report on TSE:TH stock, click here.
Theratechnologies has received FDA approval for its Prior Approval Supplement to the supplemental biologics license application for EGRIFTA SV, allowing for unrestricted distribution of the product. This approval, along with the recent approval of a new formulation, EGRIFTA WR, marks a significant step in resolving supply uncertainties and enhancing the patient experience, potentially strengthening the company’s market position in the treatment of excess abdominal fat in adults with HIV and lipodystrophy.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies is showing some financial improvements and strategic partnerships that may support long-term growth. However, high leverage, profitability issues, and technical weaknesses pose significant investment risks. While recent corporate events and earnings call insights provide some positive outlook, the overall stock score remains cautious due to these underlying challenges.
To see Spark’s full report on TSE:TH stock, click here.
Theratechnologies has received FDA approval for EGRIFTA WR™, a new formulation of tesamorelin for injection, designed to treat excess visceral abdominal fat in adults with HIV and lipodystrophy. This improved version offers a more convenient dosing schedule, requiring weekly reconstitution instead of daily, and is set to replace the current EGRIFTA SV®. The new formulation is expected to enhance patient experience and simplify administration, potentially improving management of comorbidities like lipodystrophy among HIV patients.
Theratechnologies reported record financial results for the fiscal year 2024, achieving a positive Adjusted EBITDA of $20 million, surpassing its guidance. The company also recorded a quarterly revenue of $25 million and an annual revenue of $85.9 million. New credit facilities have been secured, freeing up $19 million in cash for 2025, and the company has in-licensed two new Ionis assets in Canada to drive long-term growth. The company faced a temporary supply disruption of EGRIFTA SV® due to a shutdown of its contract manufacturer’s facility, but has resumed distribution after FDA approval to sell newly manufactured batches.